Compare BG & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BG | NTRA |
|---|---|---|
| Founded | 1818 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5B | 29.1B |
| IPO Year | 2023 | 2015 |
| Metric | BG | NTRA |
|---|---|---|
| Price | $126.46 | $212.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 15 |
| Target Price | $132.29 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.28% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $70,329,000,000.00 | $210,939,000.00 |
| Revenue This Year | $36.36 | $18.08 |
| Revenue Next Year | $3.40 | $19.65 |
| P/E Ratio | $358.26 | ★ N/A |
| Revenue Growth | ★ 32.43 | N/A |
| 52 Week Low | $71.60 | $131.81 |
| 52 Week High | $134.87 | $256.36 |
| Indicator | BG | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.60 | 51.37 |
| Support Level | $117.57 | $186.96 |
| Resistance Level | $126.62 | $222.53 |
| Average True Range (ATR) | 4.01 | 10.51 |
| MACD | 0.08 | 0.34 |
| Stochastic Oscillator | 48.24 | 51.46 |
Bunge Global SA is an agribusiness solutions company, connecting farmers to consumers and delivering essential food, feed and fuel to the globe. The company segments include Soybean Processing and Refining; Softseed Processing and Refining; Other Oilseeds Processing and Refining; Grain Merchandising and Milling; and Corporate and Other. It generates maximum revenue from the Soybean Processing and Refining segment, which includes integrated business principally involved in the purchase, storage, transportation, processing, distribution, refining, marketing, and sale of soybeans and soybean related products, as well as biodiesel and fertilizer production and distribution. Geographically, the company operates in United States, Switzerland, Netherlands, and Rest of the World.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.